title: Expedited discovery of second generation NK-1 antagonists: identification of a nonbasic aryloxy substituent.
abstract: Solution-phase, parallel-synthesis techniques were used to optimize a series of nonbasic NK-1 antagonists, resulting in the identification of (R)-26, an orally bioavailable compound with subnanomolar potency.
authors: Lilly Research Laboratories, Eli Lilly and Company, 46285, Indianapolis, IN, USA. j.fritz@lilly.com
authors: J E
authors: JE
authors: Fritz
authors: P A
authors: PA
authors: Hipskind
authors: K L
authors: KL
authors: Lobb
authors: J A
authors: JA
authors: Nixon
authors: P G
authors: PG
authors: Threlkeld
authors: B D
authors: BD
authors: Gitter
authors: C L
authors: CL
authors: McMillian
authors: S W
authors: SW
authors: Kaldor
mesh_terms: D064729:Neurokinin-1 Receptor Antagonists; D013329:Structure-Activity Relationship
chemical_list: D064729:Neurokinin-1 Receptor Antagonists